APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchHuman Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market include Weiguang Biological, CTBB, Shanghai RAAS, Nanyue Biopharming, Hualan Bio, Sinopharm, Guangdong Shuagnlin Bio-pharmacy, Boya-Bio and Beijing Tiantan Biological Products, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Company

Weiguang Biological

CTBB

Shanghai RAAS

Nanyue Biopharming

Hualan Bio

Sinopharm

Guangdong Shuagnlin Bio-pharmacy

Boya-Bio

Beijing Tiantan Biological Products

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Type

1.25g/25ml

10g/200ml

1g/20ml

2.5g/50ml

5g/100ml

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Application

Hospital

Clinic

Others

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) significant trends, drivers, influence factors in global and regions.

6. To analyze Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) industry.

Chapter 3: Detailed analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends Table 2. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers Table 3. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges Table 4. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints Table 5. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Company (2021-2026) Table 7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Company (2021-2026) Table 9. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Company Manufacturing Base & Headquarters Table 12. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company, Product Type & Application Table 13. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 1.25g/25ml Table 18. Significant Companies of 10g/200ml Table 19. Significant Companies of 1g/20ml Table 20. Significant Companies of 2.5g/50ml Table 21. Significant Companies of 5g/100ml Table 22. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Type (2021-2026) Table 26. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Type (2027-2032) Table 27. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type (2021-2026) Table 31. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Application (2021-2026) Table 39. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Application (2027-2032) Table 40. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application (2021-2026) Table 44. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application (2027-2032) Table 45. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026) & (K Units) Table 47. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2021-2026) Table 48. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2027-2032) & (K Units) Table 49. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2027-2032) Table 50. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Region (2021-2026) Table 53. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Region (2027-2032) Table 55. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 60. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2026) Table 61. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 62. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2027-2032) Table 63. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Market Share by Country (2021-2026) Table 65. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Market Share by Country (2027-2032) Table 67. Weiguang Biological Company Information Table 68. Weiguang Biological Business Overview Table 69. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 71. Weiguang Biological Recent Development Table 72. CTBB Company Information Table 73. CTBB Business Overview Table 74. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 76. CTBB Recent Development Table 77. Shanghai RAAS Company Information Table 78. Shanghai RAAS Business Overview Table 79. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 81. Shanghai RAAS Recent Development Table 82. Nanyue Biopharming Company Information Table 83. Nanyue Biopharming Business Overview Table 84. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 86. Nanyue Biopharming Recent Development Table 87. Hualan Bio Company Information Table 88. Hualan Bio Business Overview Table 89. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 91. Hualan Bio Recent Development Table 92. Sinopharm Company Information Table 93. Sinopharm Business Overview Table 94. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 96. Sinopharm Recent Development Table 97. Guangdong Shuagnlin Bio-pharmacy Company Information Table 98. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 99. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 101. Guangdong Shuagnlin Bio-pharmacy Recent Development Table 102. Boya-Bio Company Information Table 103. Boya-Bio Business Overview Table 104. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 106. Boya-Bio Recent Development Table 107. Beijing Tiantan Biological Products Company Information Table 108. Beijing Tiantan Biological Products Business Overview Table 109. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 111. Beijing Tiantan Biological Products Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors List Table 115. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Image Figure 2. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (2021-2032) & (K Units) Figure 5. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 1.25g/25ml Image Figure 10. 10g/200ml Image Figure 11. 1g/20ml Image Figure 12. 2.5g/50ml Image Figure 13. 5g/100ml Image Figure 14. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Type (2021-2032) Figure 17. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Application (2021-2032) Figure 26. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application (2021-2032) Figure 29. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 34. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 40. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • 1.25g/25ml
  • 10g/200ml
  • 1g/20ml
  • 2.5g/50ml
  • 5g/100ml
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Weiguang Biological
  • CTBB
  • Shanghai RAAS
  • Nanyue Biopharming
  • Hualan Bio
  • Sinopharm
  • Guangdong Shuagnlin Bio-pharmacy
  • Boya-Bio
  • Beijing Tiantan Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032)
  4. 1.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume (2021-2032)
  5. 1.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Dynamics
  1. 2.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends
  2. 2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers
  3. 2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges
  4. 2.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints
3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Company
  1. 3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Revenue Ranking in 2025
  2. 3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Company (2021-2026)
  3. 3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Price by Company (2021-2026)
  5. 3.5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Ranking (2024-2026)
  6. 3.6 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Product Type and Application
  8. 3.8 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Type
  1. 4.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Type Introduction
  2. 4.1.1 1.25g/25ml
  3. 4.1.2 10g/200ml
  4. 4.1.3 1g/20ml
  5. 4.1.4 2.5g/50ml
  6. 4.1.5 5g/100ml
  7. 4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Type
  8. 4.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Type
  12. 4.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Type (2021-2032)
  14. 4.3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type (2021-2032)
5 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Application
  1. 5.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Application
  6. 5.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Application
  10. 5.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application (2021-2032)
6 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Regional Sales and Value Analysis
  1. 6.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2032)
  3. 6.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021-2026
  4. 6.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2027-2032)
  5. 6.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Region (2027-2032)
  9. 6.5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032)
  12. 6.6.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032)
  15. 6.7.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032)
  21. 6.9.2 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Country, 2025 VS 2032
7 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Country-level Sales and Value Analysis
  1. 7.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  4. 7.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026)
  5. 7.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032)
  6. 7.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Weiguang Biological
  2. 8.1.1 Weiguang Biological Company Information
  3. 8.1.2 Weiguang Biological Business Overview
  4. 8.1.3 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  6. 8.1.5 Weiguang Biological Recent Developments
  7. 8.2 CTBB
  8. 8.2.1 CTBB Company Information
  9. 8.2.2 CTBB Business Overview
  10. 8.2.3 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  12. 8.2.5 CTBB Recent Developments
  13. 8.3 Shanghai RAAS
  14. 8.3.1 Shanghai RAAS Company Information
  15. 8.3.2 Shanghai RAAS Business Overview
  16. 8.3.3 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  18. 8.3.5 Shanghai RAAS Recent Developments
  19. 8.4 Nanyue Biopharming
  20. 8.4.1 Nanyue Biopharming Company Information
  21. 8.4.2 Nanyue Biopharming Business Overview
  22. 8.4.3 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  24. 8.4.5 Nanyue Biopharming Recent Developments
  25. 8.5 Hualan Bio
  26. 8.5.1 Hualan Bio Company Information
  27. 8.5.2 Hualan Bio Business Overview
  28. 8.5.3 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  30. 8.5.5 Hualan Bio Recent Developments
  31. 8.6 Sinopharm
  32. 8.6.1 Sinopharm Company Information
  33. 8.6.2 Sinopharm Business Overview
  34. 8.6.3 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  36. 8.6.5 Sinopharm Recent Developments
  37. 8.7 Guangdong Shuagnlin Bio-pharmacy
  38. 8.7.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  39. 8.7.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  40. 8.7.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  42. 8.7.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  43. 8.8 Boya-Bio
  44. 8.8.1 Boya-Bio Company Information
  45. 8.8.2 Boya-Bio Business Overview
  46. 8.8.3 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  48. 8.8.5 Boya-Bio Recent Developments
  49. 8.9 Beijing Tiantan Biological Products
  50. 8.9.1 Beijing Tiantan Biological Products Company Information
  51. 8.9.2 Beijing Tiantan Biological Products Business Overview
  52. 8.9.3 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  54. 8.9.5 Beijing Tiantan Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Analysis
  2. 9.1.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Mode & Process
  6. 9.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors
  9. 9.2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst